专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

81. 发明授权

US08716245B2 Tissue protective peptides and uses thereof 有权
标题翻译：组织保护肽及其用途
公开(公告)号：US08716245B2
公开(公告)日：2014-05-06
申请号：US13278131
申请日：2011-10-20
申请人： Anthony Cerami , Michael Brines , Thomas Coleman
发明人： Anthony Cerami , Michael Brines , Thomas Coleman
IPC分类号： C07K7/08 , A61K38/10 , A61K48/00
CPC分类号： C07K14/505 , A61K38/00 , C07K14/435 , C07K14/575 , C07K14/71 , C07K2319/00
摘要： Provided herein are tissue protective peptides derived from or sharing consensus sequences with portions of cytokine receptor ligands, including Erythropoietin (EPO), that are generally located on or within the region of the cytokine receptor ligand that faces away from a receptor complex while the ligand is bound to the receptor. Also provide herein are fragments, chimeras, as well as peptides designed to mimic the spatial localization of key amino acid residues within the tissue protective receptor ligands, e.g., EPO; methods for treating or preventing a disease or disorder using tissue protective peptides; and methods for enhancing excitable tissue function using tissue protective peptides.
摘要翻译：本文提供了组织保护肽，其衍生自或与共同序列共享，其中部分细胞因子受体配体包括促红细胞生成素（EPO），其通常位于远离受体复合物的细胞因子受体配体的区域上或内侧，而配体为与受体结合。本文还提供了片段，嵌合体以及旨在模拟组织保护性受体配体例如EPO中的关键氨基酸残基的空间定位的肽; 使用组织保护肽治疗或预防疾病或病症的方法; 以及使用组织保护肽增强可兴奋组织功能的方法。

82. 发明申请

US20120028281A1 INHIBITION OF MIGRATION INHIBITORY FACTOR IN THE TREATMENT OF DISEASES INVOLVING CYTOKINE-MEDIATED TOXICITY 审中-公开
标题翻译：抑制涉及细胞因子介导的毒性的疾病治疗中的移动抑制因子
公开(公告)号：US20120028281A1
公开(公告)日：2012-02-02
申请号：US13186657
申请日：2011-07-20
申请人： Richard J. Bucala , Robert A. Mitchell , Jurgen Bernhagen , Thierry F. Calandra , Anthony Cerami
发明人： Richard J. Bucala , Robert A. Mitchell , Jurgen Bernhagen , Thierry F. Calandra , Anthony Cerami
IPC分类号： G01N33/53
CPC分类号： C12N15/113 , A01K2217/05 , A01K2217/075 , A01K2267/03 , A01K2267/0337 , A61K48/00 , A61K2039/505 , C07K14/52 , C07K14/575 , C07K14/72 , C07K16/24 , C07K16/26 , C07K2317/73 , C07K2317/76 , C12N15/1136 , C12N15/1138 , C12N15/8509 , Y02A50/412
摘要： The present invention relates to diagnostic methods for determining migration inhibitory factor (MIF) mRNA content in a sample, wherein MIF is human MIF polypeptide having a molecular weight of approximately 12.5 kDa and kits for detecting MIF.
摘要翻译：本发明涉及用于确定样品中迁移抑制因子（MIF）mRNA含量的诊断方法，其中MIF是分子量约为12.5kDa的人MIF多肽和用于检测MIF的试剂盒。

83. 发明授权

US08071554B2 Tissue protective peptides and uses thereof 有权
标题翻译：组织保护肽及其用途
公开(公告)号：US08071554B2
公开(公告)日：2011-12-06
申请号：US11997898
申请日：2006-08-07
申请人： Anthony Cerami , Michael Brines
发明人： Anthony Cerami , Michael Brines
IPC分类号： A61K38/08 , A61K38/16 , C07K17/08
CPC分类号： C07K14/505 , A61K38/00 , C07K14/435 , C07K14/575 , C07K14/71 , C07K2319/00
摘要： The present invention is directed to novel tissue protective peptides. The tissue protective peptides of the invention may bind to a tissue protective receptor complex. In particular, the present invention is drawn to tissue protective peptides derived from or sharing consensus sequences with portions of cytokine receptor ligands, including Erythropoietin (EPO), that are not involved in the binding of the ligand to the receptor complex, e.g., to the EPO receptor homodimer. Accordingly, the tissue protective peptides of the invention are derived from the amino acid sequences of regions of cytokine receptor ligands that are generally located on or within the region of the ligand protein that is opposite of the receptor complex, i.e., are generally derived from amino acid sequences of regions of the ligand protein that face away from the receptor complex while the ligand is bound to the receptor. The invention is further directed to the consensus sequences for use in engineering a synthetic tissue protective peptide. These tissue protective peptides also include fragments, chimeras, as well as peptides designed to mimic the spatial localization of key amino acid residues within the tissue protective receptor ligands, e.g., EPO. The invention further encompasses methods for treating or preventing a disease or disorder using tissue protective peptides of the current invention. The invention also encompasses methods for enhancing excitable tissue function using tissue protective peptides of the current invention.
摘要翻译：本发明涉及新型组织保护肽。本发明的组织保护肽可以结合组织保护性受体复合物。特别地，本发明涉及来源于或共享共有序列的组织保护肽，其中部分细胞因子受体配体包括促红细胞生成素（EPO），其不参与配体与受体复合物的结合，例如与 EPO受体同二聚体。因此，本发明的组织保护肽衍生自通常位于与受体复合体相反的配体蛋白的区域上或内部的细胞因子受体配体的区域的氨基酸序列，即通常衍生自氨基当配体与受体结合时，配体蛋白的表面远离受体复合物的酸序列。本发明还涉及用于工程化合成组织保护肽的共有序列。这些组织保护肽还包括片段，嵌合体以及旨在模拟组织保护性受体配体例如EPO内的关键氨基酸残基的空间定位的肽。本发明还包括使用本发明的组织保护肽治疗或预防疾病或病症的方法。本发明还包括使用本发明的组织保护肽增强可兴奋组织功能的方法。

84. 发明申请

US20110263504A1 TISSUE PROTECTIVE PEPTIDES AND PEPTIDE ANALOGS FOR PREVENTING AND TREATING DISEASES AND DISORDERS ASSOCIATED WITH TISSUE DAMAGE 有权
标题翻译：用于预防和治疗与组织损伤相关的疾病和病症的组织保护肽和肽类似物
公开(公告)号：US20110263504A1
公开(公告)日：2011-10-27
申请号：US12863973
申请日：2009-01-22
申请人： Anthony Cerami , Michael Brines
发明人： Anthony Cerami , Michael Brines
IPC分类号： A61K38/16 , C07K7/08 , C07K14/00 , A61K38/08 , A61K38/10 , C12N15/12 , C12N15/63 , C12N1/21 , C12N5/07 , C12N5/04 , C12P21/00 , A61P35/00 , A61P29/00 , A61P9/00 , A61P11/00 , A61P13/12 , A61P13/02 , A61P15/00 , A61P19/08 , A61P17/00 , A61P1/00 , A61P5/00 , A61P3/00 , A61P25/00 , C07K7/06
CPC分类号： A61K38/1816 , A61K38/00 , A61K38/10 , C07K7/06 , C07K14/505
摘要： The present invention provides peptides and peptide analogs that have tissue protective activities while having little or no potentially undesirable hematopoietic effects. The peptides and peptide analogs are useful in preventing and treating a variety of diseases and disorders associated with tissue damage.
摘要翻译：本发明提供具有组织保护活性同时具有很少或没有潜在的不期望的造血作用的肽和肽类似物。肽和肽类似物可用于预防和治疗与组织损伤相关的各种疾病和病症。

85. 发明申请

US20110245169A1 PROTECTION, RESTORATION AND ENHANCEMENT OF ERYTHROPOIETIN RESPONSIVE CELLS, TISSUES AND ORGANS 审中-公开
标题翻译：保护，恢复和增强ERYTHROPOIETIN反应细胞，组织和器官
公开(公告)号：US20110245169A1
公开(公告)日：2011-10-06
申请号：US13036638
申请日：2011-02-28
申请人： Michael Brines , Anthony Cerami , Carla Cerami
发明人： Michael Brines , Anthony Cerami , Carla Cerami
IPC分类号： A61K38/18 , A61P25/00 , A61P27/02 , A61P9/00 , A61P13/12
CPC分类号： C07K14/505 , A61K38/1816
摘要： Methods and compositions are provided for protecting or enhancing an erythropoietin-responsive cell, tissue, organ or body part function or viability in vivo, in situ or ex vivo in mammals, including human beings, by systemic or local administration of an erythropoietin receptor activity modulator, such as an erythropoietin or a modified erythropoietin.
摘要翻译：提供了通过全身或局部施用促红细胞生成素受体活性调节剂，在哺乳动物（包括人）中原位或离体保护或增强促红细胞生成素反应性细胞，组织，器官或身体部位功能或活体活性的方法和组合物，例如促红细胞生成素或修饰的红细胞生成素。

86. 发明授权

US07517523B2 Anti-MIF antibodies 失效
标题翻译：抗MIF抗体
公开(公告)号：US07517523B2
公开(公告)日：2009-04-14
申请号：US10462751
申请日：2003-06-17
申请人： Richard Bucala , Robert A. Mitchell , Jurgen Bernhagen , Thierry F. Calandra , Anthony Cerami
发明人： Richard Bucala , Robert A. Mitchell , Jurgen Bernhagen , Thierry F. Calandra , Anthony Cerami
IPC分类号： A61K39/00 , A61K39/395 , C07K16/18 , C12P21/00
CPC分类号： C12N15/113 , A01K2217/05 , A01K2217/075 , A01K2267/03 , A01K2267/0337 , A61K48/00 , A61K2039/505 , C07K14/52 , C07K14/575 , C07K14/72 , C07K16/24 , C07K16/26 , C07K2317/73 , C07K2317/76 , C12N15/1136 , C12N15/1138 , C12N15/8509 , Y02A50/412
摘要： The present invention relates to compositions and methods for inhibiting the release and/or biological activity of migration inhibitory factor (MIF). In particular, the invention relates to the uses of such compositions and methods for the treatment of various conditions involving cytokine-mediated toxicity, which include, but are not limited to shock, inflammation, graft versus host disease, and/or autoimmune diseases.
摘要翻译：本发明涉及抑制迁移抑制因子（MIF）的释放和/或生物活性的组合物和方法。特别地，本发明涉及这种组合物和方法用于治疗涉及细胞因子介导的毒性的各种病症的用途，其包括但不限于休克，炎症，移植物抗宿主病和/或自身免疫性疾病。

87. 发明授权

US06645493B1 Composition containing anti-MIF antibody 失效
标题翻译：含有抗MIF抗体的组合物
公开(公告)号：US06645493B1
公开(公告)日：2003-11-11
申请号：US08471705
申请日：1995-06-06
申请人： Richard J. Bucala , Robert A. Mitchell , Jurgen Bernhagen , Thierry F. Calandra , Anthony Cerami
发明人： Richard J. Bucala , Robert A. Mitchell , Jurgen Bernhagen , Thierry F. Calandra , Anthony Cerami
IPC分类号： A61K3900
CPC分类号： C12N15/113 , A01K2217/05 , A01K2217/075 , A01K2267/03 , A01K2267/0337 , A61K48/00 , A61K2039/505 , C07K14/52 , C07K14/575 , C07K14/72 , C07K16/24 , C07K16/26 , C07K2317/73 , C07K2317/76 , C12N15/1136 , C12N15/1138 , C12N15/8509 , Y02A50/412
摘要： The present invention relates to compositions and methods for inhibiting the release and/or biological activity of migration inhibitory factor (MIF). In particular, the invention relates to the uses of such compositions and methods for the treatment of various conditions involving cytokine-mediated toxicity, which include, but are not limited to shock, inflammation, graft versus host disease, and/or autoimmune diseases.
摘要翻译：本发明涉及抑制迁移抑制因子（MIF）的释放和/或生物活性的组合物和方法。特别地，本发明涉及这种组合物和方法用于治疗涉及细胞因子介导的毒性的各种病症的用途，其包括但不限于休克，炎症，移植物抗宿主病和/或自身免疫性疾病。

88. 发明授权

US06174526B1 Blood-borne mesenchymal cells 失效
标题翻译：血源间充质细胞
公开(公告)号：US06174526B1
公开(公告)日：2001-01-16
申请号：US08487116
申请日：1995-06-07
申请人： Anthony Cerami , Richard J. Bucala
发明人： Anthony Cerami , Richard J. Bucala
IPC分类号： A01N6500
CPC分类号： C12N5/0665 , A61K2035/124 , A61K2039/5158 , C12N2501/22
摘要： The present invention relates to a population of blood borne mammalian cells that express a unique profile of surface markers that includes certain markers typical of connective tissue fibroblasts, and are referred to herein as “blood-borne mesenchymal cells.” In particular, it relates to the isolation, characterization and uses of such blood-borne mesenchymal cells. The cells of the present invention can be distinguished from peripheral blood leukocytes by their distinct size, morphology, cell surface phenotype and biologic activities, and are likewise distinguishable from connective tissue fibroblasts by other surface phenotypic markers. These cells proliferate in culture, and in vivo, as demonstrated in animal models, are capable of migrating into wound sites from the blood. Therefore, such blood-borne mesenchymal cells may have a wide range of applications, including, but not limited to, the promotion of wound healing, tissue remodeling, and for gene therapy.
摘要翻译：本发明涉及表达包含结缔组织成纤维细胞典型的特定标志物的表面标志物的独特特征的血液载体哺乳动物细胞群，并且在本文中称为“血源性间充质细胞”。特别地，它涉及这种血源间充质细胞的分离，表征和用途。本发明的细胞可以通过其不同的大小，形态，细胞表面表型和生物活性来区别于外周血白细胞，并且同样可以通过其他表面表型标记物与结缔组织成纤维细胞区分开来。这些细胞在培养物中增殖，并且如在动物模型中所证明的那样，能够从血液迁移到伤口部位。因此，这种血源性间充质细胞可以具有广泛的应用，包括但不限于促进伤口愈合，组织重塑和用于基因治疗。

89. 发明授权

US6103234A Composition comprising an antibody to macrophage-derived inflammatory mediator (MIP-2) 失效
标题翻译：包含来自巨噬细胞衍生的炎性介质（MIP-2）的抗体的组合物
公开(公告)号：US6103234A
公开(公告)日：2000-08-15
申请号：US476376
申请日：1995-06-07
申请人： Stephen D. Wolpe , Anthony Cerami , Barbara Sherry , Patricia A. Tekamp-Olson
发明人： Stephen D. Wolpe , Anthony Cerami , Barbara Sherry , Patricia A. Tekamp-Olson
IPC分类号： C12N15/09 , A61K38/00 , A61K39/395 , A61K45/00 , A61K47/46 , A61P29/00 , C07K14/435 , C07K14/52 , C07K16/00 , C07K16/24 , C07K19/00 , C12N1/19 , C12N5/0789 , C12P21/00 , C12P21/08 , C12R1/865 , C12R1/91 , G01N33/53 , G01N33/577 , G01N33/68
CPC分类号： C12N5/0647 , C07K14/522 , C07K16/24 , G01N33/6863 , A61K38/00 , C07K2319/02 , C12N2501/21 , C12N2501/22 , Y10S514/885
摘要： An inflammatory cytokine is disclosed which has been isolated from cells that have been incubated with a stimulator material. The inflammatory cytokine comprises a protein that is capable of binding to heparin, inducing localized inflammation characterized by polymorphonuclear cell infiltration when administered subcutaneously and having potent in vitro chemotactic activity while inducing little or no in vitro chemokinesis in polymorphonuclear cells, while lacking the ability to suppress the activity of the anabolic enzyme lipoprotein lipase, cause the cytotoxicity of cachectin/TNF-sensitive cells, stimulate the blastogenesis of endotoxin-resistant C3H/HeJ thymocytes, or induce the production of cachectin/TNF by primary thioglycollate-elicited mouse macrophage cells. A particular inflammatory cytokine has been isolated and its cDNA has been sequenced. The sequence predicts a cDNA of 74 amino acids in length and a molecular weight of 7,908. Diagnostic and therapeutic utilities are proposed, and testing procedures, materials in kit form, recombinant materials and procedures, and pharmaceutical compositions are likewise set forth.
摘要翻译：公开了已经与已经与刺激剂材料一起温育的细胞分离的炎性细胞因子。炎性细胞因子包含能够结合肝素的蛋白质，诱导局部炎症，其特征在于皮下投与多形核细胞浸润，并且具有有效的体外趋化活性，同时在多形核细胞中诱导很少或没有体外趋化因子，同时缺乏抑制能力合成代谢酶脂蛋白脂肪酶的活性引起高胆素/ TNF敏感细胞的细胞毒性，刺激内毒素抗性C3H / HeJ胸腺细胞的胚胎发生，或诱导由初级巯基乙酸酯诱导的小鼠巨噬细胞产生恶性胶质瘤/ TNF。已经分离了特定的炎性细胞因子，并对其cDNA进行了测序。该序列预测长度为74个氨基酸的cDNA，分子量为7,908。提出了诊断和治疗用途，同样阐述了测试程序，试剂盒形式的材料，重组材料和程序以及药物组合物。

90. 发明授权

US6080407A Diagnostic assays for MIF 失效
标题翻译：抑制迁移抑制因子治疗涉及细胞因子介导的毒性的疾病
公开(公告)号：US6080407A
公开(公告)日：2000-06-27
申请号：US471586
申请日：1995-06-06
申请人： Richard J. Bucala , Robert A. Mitchell , Jurgen Bernhagen , Thierry F. Calandra , Anthony Cerami
发明人： Richard J. Bucala , Robert A. Mitchell , Jurgen Bernhagen , Thierry F. Calandra , Anthony Cerami
IPC分类号： A61K39/395 , A61K48/00 , A61P43/00 , C07K14/52 , C07K14/575 , C07K14/72 , C07K16/24 , C07K16/26 , C12N15/113 , C12N15/85
CPC分类号： C12N15/113 , C07K14/52 , C07K14/575 , C07K14/72 , C07K16/24 , C07K16/26 , C12N15/1136 , C12N15/1138 , C12N15/8509 , A01K2217/05 , A01K2217/075 , A01K2267/03 , A01K2267/0337 , A61K2039/505 , A61K48/00 , C07K2317/73 , C07K2317/76
摘要： The present invention relates to compositions and methods for inhibiting the release and/or biological activity of migration inhibitory factor (MIF). In particular, the invention relates to the uses of such compositions and methods for the treatment of various conditions involving cytokine-mediated toxicity, which include, but are not limited to shock, inflammation, graft versus host disease, and/or autoimmune diseases.
摘要翻译：本发明涉及抑制迁移抑制因子（MIF）的释放和/或生物活性的组合物和方法。特别地，本发明涉及这种组合物和方法用于治疗涉及细胞因子介导的毒性的各种病症的用途，其包括但不限于休克，炎症，移植物抗宿主病和/或自身免疫性疾病。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式